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Abstract
Use of marginal liver grafts, especially those from donors after circulatory death (DCD), has
been considered as a solution to organ shortage. Inferior outcomes have been attributed to
donor warm ischaemic damage in these DCD organs. Here we sought to profile the meta-
bolic mechanisms underpinning donor warm ischaemia. Non-targeted Fourier transform ion
cyclotron resonance (FT-ICR) mass spectrometry metabolomics was applied to biopsies of
liver grafts from donors after brain death (DBD; n = 27) and DCD (n = 10), both during static
cold storage (T1) as well as post-reperfusion (T2). Furthermore 6 biopsies from DBD donors
prior to the organ donation (T0) were also profiled. Considering DBD and DCD together, sig-
nificant metabolic differences were discovered between T1 and T2 (688 peaks) that were pri-
marily related to amino acid metabolism, meanwhile T0 biopsies grouped together with T2,
denoting the distinctively different metabolic activity of the perfused state. Major metabolic
differences were discovered between DCD and DBD during cold-phase (T1) primarily
related to glucose, tryptophan and kynurenine metabolism, and in the post-reperfusion
phase (T2) related to amino acid and glutathione metabolism. We propose tryptophan/
kynurenine and S-adenosylmethionine as possible biomarkers for the previously estab-
lished higher graft failure of DCD livers, and conclude that the associated pathways should
be targeted in more exhaustive and quantitative investigations.
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Introduction
Small (<1,000 Da) metabolites regulate cell signalling, cell-to-cell communication and energy
transfer amongst other cellular processes, and are the first biochemicals to respond to internal
or external stimuli. This responsiveness makes the metabolome an informative measure of the
cell’s dynamic state, a property that has led to a considerable and growing interest in the appli-
cation of metabolomics in the health sciences. In parallel, metabolomics has begun to be used
in clinical solid organ transplantation [1,2] where it holds considerable promise for the discov-
ery of biomarkers to predict poor graft function or patient survival, as well as to elucidate the
molecular mechanisms underlying pathophysiological processes such as during graft dysfunc-
tion, injury or rejection [3]. Beginning with early studies using 1H-NMR spectroscopy, the
applications of metabolomics in transplantation have expanded in more recent publications to
using mass spectrometry based profiling of poor allograft function [4]. Case studies using
NMR spectroscopy identified six potential metabolic biomarkers that were distinctive of a
non-functional liver[5,6]. Meanwhile a metabolomics assessment in cirrhotic patients by
1H-NMR spectroscopy linked elevated levels of high-density lipoproteins and phosphocholine
with mild chronic liver failure whereas elevated levels of lactate, pyruvate, glucose and creati-
nine were associated with severe chronic liver failure (CLF). This study provided new insights
to hepatic functional impairment in cirrhosis as well as showed an alternative approach to
evaluate the severity of CLF, a key aspect in therapeutic decision making [7]. Furthermore,
analyses of human bile during liver transplantation by capillary electrophoresis showed dis-
tinct metabolic fingerprints in donors and recipients [8]. Whereas more recent publication has
been focussed on much larger group of liver grafts belonging to two distinct organ donor
sources, namely the cadaveric donation after circulatory death (DCD), and donation after
brain death (DBD) and applied lipidomics studies identify markers of early allograft dysfunc-
tion [9].
While liver transplantation is well established as the treatment of choice for many indica-
tions, the ever growing number of patients listed for transplantation has outweighed the supply
of cadaveric organs, leading to greater disparity between supply and demand. As a result, most
transplant programmes turned to using marginal organs, in particular liver grafts obtained by
donation after circulatory death (DCD), to supplement more traditional donation after brain
death (DBD) [10]. Despite rigorous donor selection criteria and best efforts to match a DCD
graft with an optimal recipient, the results of the DCD transplantations remain inferior to the
standard DBD transplantations and include increased occurrence of primary non-function
(PNF) and biliary complications in the immediate post-operative period as well as inferior
long-term graft survival rates [11–13]. These complications have been initially associated with
donor warm ischaemia (Greek; isch–restriction, hema—blood), typical of DCD grafts during
the surgical withdrawal phase. This phase is of variable and unpredictable duration which each
DCD donor undergoes once the life support therapy is halted to allow natural passage to circu-
latory death [14]. Furthermore, grafts obtained from deceased donors are typically stored on
ice (at a temperature between 0–4˚C) before these organs are transplanted to the recipient, and
this phase of cold storage further aggravates graft injury due to ischaemia [15]. Once the blood
supply is reconnected within the recipient (both DCD and DBD) to the transplanted organs
(termed reperfusion), further organ injury occurs through a process known as ischaemia-
reperfusion or preservation-reperfusion injury. In this multifactorial process the reactive oxy-
gen species generated in the organ during warm ischaemia initiate a cellular cascade leading to
inflammation, and in severe cases to organ failure termed as PNF [16,17].
Identifying the metabolic differences between DCD and DBD liver grafts could significantly
improve current clinical practise by defining biomarkers that are predictive of poor graft
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function prior to transplantation. Selection of grafts from donors that exhibit such metabolic
biomarkers could assist in clinical decision making and the exclusion of those organs from
transplantation, thereby preventing the adverse clinical sequelae after transplantation. This
would also help those transplant programs that are reliant on cadaveric donor organs for trans-
plantation by preventing the necessity to perform re-transplant operations on those who had
failed liver grafts, minimising the burden and demand for organs. Furthermore, identifying
the metabolic differences between DCD and DBD liver grafts could help to identify the meta-
bolic modifications of livers prior to and after the organ procurement from the donor that
would improve the organ quality, an approach called metabolic therapy. This approach is justi-
fied by the nature of current organ donation practice. In the United Kingdom alone there has
been a steep rise in DCD donations in recent years, however only 27% of liver grafts from
these donors are used in clinical transplantation [18] with approximately 8% of these being
excluded due to the high risk of PNF. In addition, the majority of grafts are not even procured
due to increased time elapsed between the treatment withdrawal phase and circulatory death,
which is beyond the currently accepted criteria of donor warm ischaemia time (30 minutes).
Relating the metabolic profiles of DCD and DBD liver grafts to the outcome of the transplanta-
tion could supplement and expand the traditional methods to predict organ function, in par-
ticular early on during the transplantation procedure.
Previously we reported a pilot study that demonstrated the potential of Fourier transform
ion cyclotron resonance (FT-ICR) mass spectrometry to detect a few thousand metabolic fea-
tures (or peaks) in biopsies obtained from liver grafts in the cold and post-reperfusion phases
of orthotopic liver transplantation (OLT)[19]. We observed and characterized changes in mul-
tiple metabolic pathways showing a rapid resumption of biochemical function within the grafts
following reperfusion [19]. Here, we expand considerably upon this initial investigation, spe-
cifically with the aim to investigate and characterize the metabolic differences between DCD
and DBD liver grafts at two key phases of the liver transplantation, the cold storage phase (T1)
and post-reperfusion phase (T2). We seek to reveal the underlying metabolic pathways associ-
ated with the clinical observation of reduced success of the DCD grafts.
Materials and Methods
This study was approved by the South Birmingham Regional and National Research Ethics
committee. The study was aimed at discovery of biomarker differences in the liver grafts used
in the clinical orthotopic liver (OLT) setting with possibility of identifying those that may pre-
dict poor graft function and primary non-function. Considering the inferior clinical outcomes
reported from DCD liver transplantation, we specifically focussed on identifying whether
metabolite features differed between DCD and DBD liver grafts. Biopsies were obtained while
the grafts were in an ice bath after a variable period of cold ischaemia had elapsed, and again in
the post reperfusion phase. In a limited number of patients biopsied were also obtained in the
pre-donation setting. All recipients involved were adequately informed and signed a consent
form.
Clinical data
Overall, a total of 37 (DBD; n = 27 and DCD; n = 10) liver grafts were studied and the clinical
courses of the recipients were followed. In DBD donors, the brain stem death criteria had been
confirmed prior to the donor operation, which involved dissection and isolation of graft blood
vessels while the circulatory function was intact. In DCD donors (n = 10), death was confirmed
according to the Institute of Medicine guidelines after obligatory 5 minutes standoff time from
the circulatory arrest, after which the donor operation was performed as rapidly as possible
Metabolomic Differences between Cadaveric Graft Types
PLOS ONE | DOI:10.1371/journal.pone.0165884 November 11, 2016 3 / 16
[14]. The technical aspects of the organ procurement were otherwise similar. Both in the DBD
and DCD procedures, grafts were perfused with Hyper-Osmolar Citrate (HOS, via cannula
inserted to the aorta) and University of Wisconsin (UW, via portal vein) preservation fluids.
Following donor operations, the liver grafts were packed on ice and transported to the location
of the recipient operation, where the grafts were prepared for implantation while immersed in
an ice bath. A wide spectrum of procedure related parameters as well as patient demographics
and outcome data were recorded for comparison. These included cold ischaemia time (CIT)
elapsed prior to the bench biopsy, overall CIT, donor warm ischaemia time (dWIT) in DCD,
immediate post operative outcomes, acute physiological status of the recipient while in the
intensive care unit, basic liver graft functions, episodes of graft rejection, graft failures and sur-
vival outcomes.
Patients underwent OLT for a variety of indications including alcoholic liver disease, pri-
mary biliary cirrhosis, primary sclerosing cholangitis, viral hepatitis (HBV/HCV), non-alco-
holic steatohepatitis, polycystic disease, Cryptogenic/Autoimmune and Wilson’s disease. The
median age of recipient was 53 and 56 years for DCD and DBD respectively. The median
(range) model for end-stage liver disease scores of DCD and DBD graft recipients were 12 (8–
22) and 16 (6–22) respectively (Table 1).
Liver samples were obtained by Menghini biopsy needle [11520–19, 19swg (1.0mm) x
70mm; Dixons Surgical Instruments Ltd, Wickford, Essex, UK] for all 37 liver grafts at two
stages of OLT: T1 –after organ retrieval and transportation to the implanting centre while the
liver was prepared on the bench while immersed in an ice bath at a temperature of 0–4˚C
T1and T2 (post reperfusion biopsy) once the graft had been reconnected and the patient hae-
modynamics stabilised, and usually towards the end of the recipient procedure, after warm
ischaemic period and reperfusion injury. In addition, for six DBD grafts an additional biopsy
was taken at T0, during the donor surgical phase while the liver was still in the donor’s body
cavity. There were 80 liver allograft biopsies and these were snap frozen in liquid nitrogen and
stored at -80˚C until sample preparation for the direct infusion FT-ICR mass spectrometry
based metabolomics.
Direct infusion FT-ICR mass spectrometry based metabolomics
Samples were prepared for the metabolomics analysis as described previously [19]. Briefly,
biopsies were extracted using a methanol:chloroform:water method, separating the extracts
into polar and non-polar fractions [20]. In total, 80 samples liver biopsy samples were
extracted and from these one quality control (QC) sample was prepared by pooling a fraction
of each of the 80 extracts (which was then aliquoted into 11 identical fractions). The polar
metabolite fraction of each sample was analysed by USA; LTQ FT Ultra) from m/z 70 to 590,
in positive ion mode, using the SIM-stitching approach [21]. Each sample was analysed in trip-
licate. To minimise false positive metabolites in the data matrix (due to noise), only peaks pres-
ent in at least 2 of the 3 replicate measurements of each sample were retained, and then only
peaks present in at least 75% of all the samples were retained for further analysis [22]. This
data processing also served to exclude any peaks in the mass spectra that arose from the drugs
that were known to be administrated to the donors and recipients. The final data matrix con-
sisted of 1260 reproducibly detected peaks (rows) and 91 variables (80 biopsies and 11 quality
control samples; columns). The matrix contained 9.29% of missing data which was imputed
using a weighted k-nearest neighbours algorithm (k = 5) [23]. Data were then normalized
using the probabilistic quotient method [24] and subjected to a generalised log transformation
(prior multivariate analysis) to stabilise the technical variance across the peaks and hence to
avoid the highest abundance peaks from dominating the multivariate analysis [25]. Putative
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metabolite names were assigned to the peaks based on their mass-to-charge ratio and taking
into account commonly detected ions forms, including [M-e]+, [M+H]+, [M+Na]+, [M+39K]+,
[M+41K]+, [M+2Na-H]+, [M+239K-H]+ and [M+NH4]
+.
Statistical analyses
Potential clinical differences between DBD and DCD grafts were evaluated by testing each
OLT variable, including cold ischaemia time, warm ischaemia time, hours in ITU, number of
days-in hospital following OLT, peak aspartate transaminase (AST), and incidence of primary
Table 1. Donor and recipient demographics and surgical data.
DBD (n = 27) DCD (n = 10) p-value
Donor gender
• Male
•Female
•
• 11 (41%)
•16 (59%)
•
• 2 (20%)
• 8 (80%)
0.440
Donor age 50.0 (14.2) 49.7 (12.8) 0.948
Donor BMI 26.0 (5.4) 25.4 (3.0) 0.738
Donor cause of death
• ICH
• Head Injury
• Cardiac Arrest
• Other
• 18 (67%)
• 3 (11%)
• 1 (3%)
• 5 (19%)
• 4 (40%)
• 1 (10%)
• 2 (20%)
• 3 (30%)
0.294
Graft CIT 484.5 (143.6) 461.0 (117) 0.646
dWIT - 19.9 (5.7)
Graft microsteatosis • None (4)
• Mild (22)
• Moderate (1)
• None (2)
• Mild (8)
Graft macrosteatosis • None (2)
• Mild (19)
• Moderate (3)
• Severe (3)
• None (1)
• Mild (6)
• Severe (3)
Recipient gender
• Male
• Female
• 17 (63%)
• 10 (37%)
• 5 (50%)
• 5 (50%)
0.708
Recipient age 53.7 (9.1) 52.9 (7.3) 0.812
Recipient aetiology
• ALD
• HCV
• PSC
• PBC
• PCLD
• Other
• 9 (33%)
• 4 (15%)
• 2 (7%)
• 4 (15%)
• 2 (7%)
• 6 (23%)
• 5 (50%)
• 2 (20%)
• 1 (10%)
• 1 (10%)
• 1 (10%)
• 0
0.681
Presence of HCC 3 (11%) 3 (30%) 0.166
Recipient MELD 16.2 (5.1) 12.3 (4.1) 0.036
Graft Implantation time (minutes) 46.9 (15.9) 40.7 (15.8) 0.296
Operating time (minutes) 276.7 (71.7) 320.2 (98.3) 0.148
Peak AST 1783.5 (2088.2) 3374.7 (2641.3) 0.064
Days on ITU 2.5 (3.0) 5.4 (9.5) 0.160
Length of hospital stay (days) 13.9 (8.5) 14.5 (5.5) 0.825
Values expressed as mean (standard deviation) or number (percentage) as appropriate. Bold values indicate a significant difference (p<0.05) between
donor types by ANOVA, t-test or Chi-square as appropriate. ALD = Alcoholic liver disease; AST = aspartate aminotransferase; BMI = Body mass index;
CIT = Cold ischaemic time; DBD = Donation after brain death; DCD = Donation after circulatory death; HBV = Hepatitis B; HCC = Hepatocellular carcinoma;
HCV = Hepatitis C; ICH = Intracranial haemorrhage; MELD = Model for end-stage liver disease; PBC = Primary biliary cirrhosis; PCLD = Polycystic liver
disease; PSC = Primary sclerosis cholangitis; dWIT = Donor warm ischaemic time (DCD only)
doi:10.1371/journal.pone.0165884.t001
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non-function. Non-parametric 2-sample Wilcoxon rank-sum test was applied for continuous
numerical variables (e.g., CIT) and Fisher’s exact tests was used for binary variables (e.g., the
occurrence of primary non-function). The obtained p values were adjusted for multiple
hypothesis testing using the Benjamini and Hochberg method to control the false discovery
rate [26].
Principal component analysis (PCA) was used to represent the multivariate FT-ICR mass
spectral metabolomics data in 2-dimensional space in terms of principal components PC1 and
PC2. Univariate statistical analysis, on a per peak basis, was used to discover if any metabolites
differed significantly a) between donor (T0), cold (T1) and post-reperfusion (T2) phases across
all patients, and b) between DCD and DBD grafts in the cold phase (T1) and, separately, post-
reperfusion (T2) phase. Here, the Anderson-Darling test was used to evaluate normality
assumptions, and since ca. 40% of the peaks did not follow a normal distribution, non-
parametric statistical methods were used, specifically a two-sample Wilcoxon rank-sum test
(DCD and DBD comparison) and its extension to more groups, Kruskal-Wallis one-way anal-
ysis of variance (T0, T1 and T2 comparison), both with a Benjamini and Hochberg false discov-
ery correction. In addition, Gain Scores Analysis (Kruskal-Wallis on gain scores) was used to
discover those metabolites that changed in a significantly different manner from cold-phase to
post-reperfusion between the DCD and DBD grafts. FDR of 5% was used as cut-off values to
identify statistically significant features. All statistical analyses were carried out using R version
3.0.2, a free programming language and software for statistical computing and graphics. Puta-
tively identified metabolites were assigned to KEGG metabolic pathways, as defined in the
KEGG database [27,28]
Results and Discussion
Clinical outcomes
The liver transplantation procedures were carried out in a similar manner for DBD and DCD
grafts and we did not notice any significant differences neither at the procedure level nor with
the short-term outcomes. The mean CIT was 484.52 ± 143.59 minutes (DBD) and
461.00 ± 116.97 minutes (DCD), whereas the mean implantation time, when grafts were
exposed to further warm ischaemia until the circulation was restored, was 41.85 ± 6.94 minutes
(DBD) and 41.80 ± 9.77minutes (DCD). The recipients spent on average 95.04 ± 120.80
(DBD) and 123.22 ± 174.48 (DCD) hours in the intensive care unit. The majority of OLTs
were successful; three patients in the entire study group had perioperative mortality (n = 2 in
the DBD group). The causes of death were related to PNF in two patients (one patient each in
the DCD and DBD groups) and related to hepatic artery thrombosis in the third patient
(DBD) (Table 1).
Changes in hepatic metabolism during transplantation
FT-ICR mass spectra of the extracted biopsies contained 1260 reproducibly detected peaks of
which 448 (35.56%) were putatively annotated based upon accurate mass measurements and
the Kyoto Encyclopaedia of Genes and Genomes database (S1 Table). Principal component
analysis verified the high technical reproducibility of the mass spectra, evidenced by the clus-
tering of the measurements of the QC sample on the PCA scores plot (Fig 1). Furthermore, the
PCA scores showed a clear separation between the biopsies from the cold phase (T1) and post
reperfusion (T2). The clustering of the donor biopsies (T0; obtained from six DBD grafts while
the organs were still perfused with warm circulation) close to the post-reperfusion biopsies
(T2), with both groups having very distinctive metabolic profiles compared to the biopsies
originating from the cold phase sampling is a striking result (Fig 1). This signifies the
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distinctively different metabolism of hepatocytes in the perfused state compared to those in
cold storage. This metabolic separation was confirmed by univariate testing that detected 688
(54.60%) significantly different peaks between T1 and T2, 293 peaks (23.25%) between T0 and
T1, and only 124 peaks (9.84%) between T0 and T2 (Kruskal-Wallis test, p< 0.05) (Table 2). In
our previous proof-of-principle OLT study, we identified a plethora of metabolic responses in
the post-reperfused grafts compared to their cold-phase state and concluded that these changes
reflected the rapid resumption of the biochemical functions of hepatocytes following reperfu-
sion, including increased urea production, bile acid synthesis and clearance of the preservation
solution. Here, in addition to verifying these expected metabolic responses, we observed addi-
tional key metabolic changes including, amongst others, putatively annotated essential
Fig 1. Principal component analysis scores plot showing the similarities and differences between the metabolic profiles of
the grafts in donor (T0), cold (T1) and post-reperfusion phases (T2). The variance explained by PC1 = 39.82% and PC2 = 29.58.
The close grouping of the donor and post-reperfusion biopsies along with their clear separation from the cold-phase biopsies (along
PC1) is further supportive of the rapid resumption of the biochemical functions in the reperfused grafts and shows the direction of
metabolic changes through the patient journey and the OLT procedure—from ‘healthy’ donor grafts through cold-phase to almost
fully functional grafts post reperfusion.
doi:10.1371/journal.pone.0165884.g001
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Table 2. Top putatively annotated metabolic fold-changes (FC) in the liver grafts between donor phase (T0), cold phase (T1) and post-reperfusion
phase (T2), considering the DBD and DCD biopsies as one group. The average absolute ppm error was 0.3631, range: 0.0029–0.9828.
Putative metabolite m/z
(observed)
Empirical
formula
Ion FC: T2/
T1
FC: T2/
T0
FC: T1/
T0
Significance Univariate
rank
PC1 rank
Histidine* 178.05876 C6H9N3O2 Na, H, 39K 3.88 1.43 0.37 T1 vs. T2; T1 vs.
T2
1, 117, 181 1, 130, 198
Malate 157.01079 C4H6O5 Na, 2K-H 4.61 1.64 0.36 T1 vs. T0; T1 vs.
T2
3, 259 58, 116
Glutamate* 170.04244 C5H9NO4 Na, 2Na-H 5.14 1.69 0.33 T1 vs. T0; T1 vs.
T2
13, 37 15, 20
Serine 128.03181 C3H7NO3 Na, 2Na-H, K
(39), H
2.95 1.77 0.60 T1 vs. T0; T1 vs.
T2
15, 19, 143,
203
101, 105,
111, 205
Glutamine 169.05842 C5H10N2O3 Na, 39K, 2K-H 4.51 1.41 0.31 T1 vs. T0; T1 vs.
T2
16, 161, 233 12, 128, 172
N-Acetyl-L-glutamate 212.05305 C7H11NO5 Na 3.60 2.81 0.78 T1 vs. T2; T0 vs.
T2
18 30
O-Phospho-L-serine 207.99835 C3H8NO6P Na, H, 39K 6.14 1.37 0.22 T1 vs. T0; T1 vs.
T2
20, 84, 146 23, 56, 152
Tyrosine 204.06321 C9H11NO3 Na, H 3.46 1.32 0.38 T1 vs. T0; T1 vs.
T2
23, 175 25, 90
AT0P* 472.00083 C10H15N5O10P2 2Na-H, Na 5.46 1.11 0.20 T1 vs. T0; T1 vs.
T2
26, 51 45, 84
CT0P-choline 489.11491 C14H26N4O11P2 H 0.42 1.16 2.73 T1 vs. T0; T1 vs.
T2
49 41
Mannitol* 223.04042 C6H14O6 41K 0.03 1.34 46.97 T1 vs. T0; T1 vs.
T2
61 4
Taurine 148.00390 C2H7NO3S Na 2.11 1.15 0.55 T1 vs. T0; T1 vs.
T2
88 109
Citrate 193.03435 C6H8O7 H 0.20 2.44 12.14 T1 vs. T0; T1 vs.
T2
97 92
Threonine 142.04748 C4H9NO3 Na 2.76 1.37 0.50 T1 vs. T2 110 66
T2oline 138.05256 C5H9NO2 Na, H 2.40 2.75 1.14 T1 vs. T2; T0 vs.
T2
115, 221 235, 331
GMP 386.04730 C10H14N5O8P Na 3.03 0.98 0.32 T1 vs. T0; T1 vs.
T2
140 147
Glucose 221.02478 C6H12O6 41K 0.38 0.85 2.25 T1 vs. T0; T1 vs.
T2
153 114
Glycocholate* 488.29844 C26H43NO6 Na 4.49 3.27 0.73 T1 vs. T2 154 170
Succinate 141.01584 C4H6O4 Na 0.49 1.06 2.17 T1 vs. T0; T1 vs.
T2
185 106
Valine 140.06820 C5H11NO2 Na, 39K, H 2.63 1.44 0.55 T1 vs. T2 186, 218, 253 260, 272,
281
Choline 145.06889 C5H14NO 41K 2.01 2.73 1.36 T1 vs. T2; T0 vs.
T2
199 377
Formate 90.97661 CH2O2 2Na-H 5.37 3.47 0.65 T1 vs. T2 205 582
O-Phospho-L-
homoserine
200.03205 C4H10NO6P H 2.87 1.35 0.47 T1 vs. T2 209 83
Kynurenine 209.09221 C10H12N2O3 H 1.78 2.76 1.55 T1 vs. T2; T0 vs.
T2
232 338
Aspartate 134.04479 C4H7NO4 H 2.56 1.17 0.46 T1 vs. T0; T1 vs.
T2
243 139
Urea* 98.99550 CH4N2O 39K 2.48 1.31 0.53 T1 vs. T2 268 308
*
, metabolic changes observed, verifying those reported in our proof-of-principle study[19]
doi:10.1371/journal.pone.0165884.t002
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(threonine and valine) and non-essential (tyrosine, serine and proline) amino acids, taurine (a
major constituent of bile), and kynurenine (a central compound in the tryptophan metabolism
pathway.
Hepatic metabolism in DBD compared to DCD grafts
We identified a small subset of peaks that distinguished the DCD and DBD grafts at the meta-
bolic level. In particular, we detected 50 peaks including 11 putatively annotated compounds
that differed between DCD and DBD in the cold phase (T1), 64 peaks (10 putatively annotated)
that differed between DCD and DBD following reperfusion (T2), and 72 peaks (10 putatively
annotated) that changed from T1 to T2 in a significantly different manner between DCD and
DBD grafts (Table 3). The PCA scores plots, based only on these sub-selections of peaks, pro-
vide a visualisation of the clear separation of the DCD vs. DBD grafts along PC1 for the cold-
phase biopsies and almost as clear separation for the post-reperfusion biopsies (Fig 2)
The key metabolic differences between DBD and DCD grafts in the cold phase (T1)
included increased levels (in DCD) of the putatively annotated metabolites tryptophan,
Table 3. Top putatively annotated metabolic fold-changes between the DCD and DBD grafts: combined results for the comparison, (i) in the cold
phase (T1), (ii) following reperfusion (T2), and (iii) in response from going from T1 to T2. The average absolute ppm error was 0.2758, range: 0.0069–
0.6835.
Putative metabolite m/z (observed) Empirical formula Ion Fold-change DCD/DBD1 Univariate Rank2
Tryptophan 205.09725 C11H12N2O2 H 1.88T1, 1.10T2 3T1, 28G
Adenylosuccinate 464.08155 C14H18N5O11P H 0.40T1 6T1
GMP 402.02124 C10H14N5O8P 39K 0.47T1 15T1
Malate 210.94066 C4H6O5 2K-H 0.44T1 18T1
ADP 465.99284 C10H15N5O10P2 39K 0.41T1 20T1
D-Glucose 203.05261 C6H12O6 Na 1.72T1, 1.22T2 22T1, 9G
ADP 450.01895 C10H15N5O10P2 Na 0.53T1 25T1
O-Acetyl-L-carnitine 204.12305 C9H18NO4 -e 0.45T1 28T1
Kynurenine 209.09221 C10H12N2O3 H 1.80T1 43T1
Leucine 132.10190 C6H13NO2 H 1.49T1 47T1
Pantothenate 220.11806 C9H17NO5 H 0.60T1 49T1
Glutathione 352.05497 C10H17N3O6S 2Na-H 1.13T1, 1.88T2 3T2, 38G
Threonine 142.04748 C4H9NO3 Na 1.37T1, 2.07T2 4T2, 70G
Leucine 154.08388 C6H13NO2 Na 1.37T2 16T2
Glutamate 170.04244 C5H9NO4 Na 0.99T1, 1.61T2 25T2, 72G
Creatine 154.05872 C4H9N3O2 Na 1.45T2 32T2
Glutamate 192.02440 C5H9NO4 2Na-H 1.01T1, 2.78T2 38T2, 45G
Threonine 120.06551 C4H9NO3 H 1.37T2 41T2
T2oline 138.05256 C5H9NO2 Na 1.59T2 53T2
Pantothenate 220.11806 C9H17NO5 H 0.79T2 62T2
Leucine 132.10190 C6H13NO2 H 1.32T2 64T2
Ornithine 133.09716 C5H12N2O2 H 1.98T1, 1.05T2 42G
Serine 150.01378 C3H7NO3 2Na-H 0.78T1, 3.01T2 54G
SAM 399.14460 C15H22N6O5S H 1.23T1, 0.68T2 51G
Glucose 221.02478 C6H12O6 41K 1.40T1, 1.05T2 59G
1 Fold-change calculated for the corresponding phase, cold phase (T1) or post reperfusion (T2)
2 Ranking carried out separately for the three comparisons: in the cold phase (T1), post-reperfusion (T2) or based on the Gain Scores Analysis (G):
capturing the metabolic responses between DCD and DBD grafts from the T1 to T2
doi:10.1371/journal.pone.0165884.t003
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kynurenine, glucose and leucine and decreased levels of adenylosuccinate, GMP, ADP, malate,
O-acetyl carnitine and pantothenate (Table 3). The observed putative metabolites are involved
mainly in tryptophan metabolism, purine metabolism, oxidative phosphorylation and a set of
carbohydrate metabolic pathways, including the TCA cycle, pyruvate metabolism, glycolysis/
gluconeogenesis and the pentose phosphate pathway (Table 4). Among these findings, trypto-
phan and its metabolism have received earlier attention in the liver transplantation field. Tryp-
tophan is an essential amino acid that, amongst other roles, serves as a precursor of the
neurotransmitter serotonin and vitamin B3. Histidine-tryptophan-ketoglutarate (HTK) solu-
tion, which contains tryptophan to prevent membrane injury, was proposed as an alternative
liver preservation solution to the current gold standard, University of Wisconsin solution.
Interestingly the organ preservation solutions used in this study cohort (UW solution and
Hyper-osmolar citrate/Marshall’s solution) do not have added tryptophan. The systematic
review to compare the efficacy and safety of these two solutions did not show overall signifi-
cant differences, yet in some cases HTK was believed to perform better, especially in terms of
biliary tract flush and prevention of biliary complications [29]. Furthermore, tryptophan can
be catabolised either via the kynurenine or serotonin pathways, and hence kynurenine was
studied previously to investigate tryptophan metabolism in potential cirrhotic liver transplant
Fig 2. Principal component analysis scores plots highlighting the metabolic separation of the DBD and DCD grafts in the cold phase (T1) and
separately the post-reperfusion phase (T2), based on analyses of just the 50 and 64 peaks identified as being significantly different (between
DBD and DCD) for the T1 and T2 groups, respectively. Variance explained for T1, PC1 = 36.75% and PC2 = 19.39% and for T2, PC1 = 25.22% and
PC2 = 17.41%.
doi:10.1371/journal.pone.0165884.g002
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recipients. The pre-transplant serum levels of kynurenine as well as the kynurenine/trypto-
phan ratios were positively correlated with the disease severity, while serum levels of trypto-
phan and serotonin showed no correlation[30]. The significantly higher levels of tryptophan
and kynurenine in DCD grafts (vs. DBD grafts) during the cold phase in our study appears to
support the previous studies that identified tryptophan metabolism via kynurenine pathways
as a key metabolic change in liver transplantation. Although it was not a key objective to ana-
lyse biomarkers related to primary non-function in the present study given the small sample
size, the two failed allografts due to primary non-function both had abundantly higher levels
of tryptophan and kynurenine (Fig 3).
The putatively annotated metabolites that significantly differed between DCD and DBD
grafts following reperfusion (T2) included increased levels (in DCD) of glutathione, threonine,
leucine, glutamate, creatine, glutamate, proline and decreased levels of pantothenate (Table 2).
In addition, four of these metabolites including glutathione, threonine, glutamate and gluta-
mate were changed in a significantly different manner in DCD and DBD grafts while they
were removed from cold storage (T1) and following reperfusion (T2). The remaining six
metabolites identified as different in the Gain Scores Analyses included tryptophan and glu-
cose (previously observed as significantly different in the cold-phase) as well as ornithine, ser-
ine, S-adenosyl methionine (SAM) and glucose (Table 2 and Fig 4). All of these putatively
annotated metabolites are primarily involved in amino acid metabolism and translation
Table 4. Metabolic pathways discovered to differ significantly between DCD and DBD grafts, including the associated putatively annotated metab-
olites in those pathways.
Metabolic pathway Putative metabolite Description1
Tryptophan metabolism Tryptophan, Kynurenine Amino acid metabolism; T1H
Purine metabolism Adenylosuccinate, GMP, ADP Nucleotide metabolism; T1L
Oxidative phosphorylation ADP Energy metabolism; T1L
TCA cycle Malate Carbohydrate metabolism; T1L
Pyruvate metabolism Malate Carbohydrate metabolism; T1L
Glycolysis / Gluconeogenesis Glucose Carbohydrate metabolism; T1H
Pentose phosphate pathway Glucose Carbohydrate metabolism; T1H
Alanine, aspartate and glutamate metabolism Adenylosuccinate, Glutamate Amino acid metabolism; T1L, PRH
Glycine, serine and threonine metabolism Tryptophan, Threonine, Creatine, Serine Amino acid metabolism; T1H, PRH
Cysteine and methionine metabolism Glutathione, Serine, SAM Amino acid metabolism; T2 H with exception of
lower levels of SAM
Arginine and proline metabolism Glutamate, Creatine, Proline, Ornithine, SAM Amino acid metabolism; T2 H with exception of
lower levels of SAM
Valine, leucine and isoleucine degradation &
biosynthesis
Leucine, Threonine Amino acid metabolism; T1H, PRH
Glutathione metabolism Glutathione, Glutamate, Ornithine Metabolism of other amino acids; PRH
Taurine and hypotaurine metabolism Glutamate Metabolism of other amino acids; PRH
D-Glutamine and D-glutamate metabolism Glutamate Metabolism of other amino acids; PRH
Aminoacyl-tRNA biosynthesis Tryptophan, Leucine, Threonine, Glutamate, Proline,
Serine
Translation; T1H, PRH
ABC transporters Glucose, Leucine, Glutathione, Glutamate, Proline,
Ornithine, Serine
Membrane transport; T1H, PRH
Pantothenate and CoA biosynthesis Pantothenate Metabolism of cofactors and vitamins; T1L, PRL
Vitamin digestion and absorption Pantothenate Digestive system; T1L, PRL
Bile secretion Glucose, Glutathione Digestive system; T1H, PRH
1
, H, higher levels and L, lower levels of putative metabolites in DCD in the corresponding OLT stage (T1 or T2)
doi:10.1371/journal.pone.0165884.t004
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(aminoacyl-tRNA biosynthesis) and to a lesser extent in metabolism of cofactors and vitamins
and bile secretion (Table 3). Interestingly, in DBD grafts, there is a large increase in SAM
between the cold phase and post-reperfusion, which does not occur in DCD grafts. While the
biochemical implications of this lack of recovery are unknown, we hypothesise that this could
affect methylation reactions including DNA methylation, given the importance of this metabo-
lite as a methyl donor [31]. Further targeted investigations of the SAM (and related S-adeno-
sylhomocysteine) metabolic pathway are therefore warranted.
The increased level of glutathione in DCD grafts, which occurs in the cold phase (1.13
times higher in DCD compared to DBD grafts) but is considerably more pronounced (1.88
times higher) following reperfusion, is also an intriguing finding. Glutathione, owing to its
thiol group, is known as one of the most effective antioxidants preventing cellular damage
caused by reactive oxygen species, as occurs in ischaemia/reperfusion injury. One of its precur-
sors, acetylcysteine, has been studied as a protective molecule in the perioperative treatment of
patients undergoing liver transplantation [32]. Our findings show that not only were glutathi-
one levels increased but so were other intermediates of glutathione metabolism such as gluta-
mate and ornithine, indicative of disruption to the glutathione pathway. While glutathione
and glutamate shared similar responses at the post-reperfusion time point, i.e. a rapid increase
of levels in DCD compared to DBD, ornithine levels were higher in the cold-phase and similar
following reperfusion (Fig 4). This could be due to ornithine being used up for the biosynthesis
of glutathione via the intermediate by-product of glutamate. These changes may explain the
increased oxidative stress incurred by the DCD grafts, owing to the increased ischaemic injury
through warm ischaemic damage.
Although metabolomics studies have caused initial enthusiasm in the transplant commu-
nity as a potential investigative tool to differentiate poorly functioning grafts from those that
perform well after transplantation certain limitations have halted the wider applicability. Only
Fig 3. Selected top putatively identified metabolites changed in a significantly different way from the cold phase (T1) to post-reperfusion (T2)
between DCD and DBD grafts. Gain Scores Analysis (Kruskal-Wallis on gain scores) was used to discover those metabolites that changed in a
significantly different manner from cold-phase to post-reperfusion between the DCD and DBD grafts.
doi:10.1371/journal.pone.0165884.g003
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one recent publication proposes a metabolic biosignature, based on combination of metabo-
lites altered in liver allografts that perform unsatisfactorily following liver transplantation[4]
and this by far the most explicit application of metabolomics in the field of solid organ trans-
plantation. These metabolites responsible for early allograft dysfunction and graft failure
include phospholipid metabolism, bile production, ammonia and urea cycles as well as and
glutathione metabolism. Interesting some of the metabolites have also been identified in our
study, the key metabolite changes related to tryptophan and kynurenine metabolism have not
been identified that could be explained by differences in allograft allograft types and analytical
techniques involved.
Conclusions
Previous studies on larger cohorts (n > 300) of DBD and DCD liver transplantations provide
evidence for the inferiority of the DCD donations, including increased incidence of primary
non-function, biliary complications as well as lower graft- and patient survival [12,33]. Our
study has for the first time identified, in un-targeted manner, key metabolic differences
between DCD and DBD liver grafts. Since we did not observe any significant differences
between the DCD and DBD procedures and outcomes in our study, we believe that these met-
abolic differences are reflective of the inherent molecular dissimilarities between DCD and
Fig 4. The differences between tryptophan and kynurenine in failed allografts due to Primary non-function/PNF (n = 2) vs. non-PNF (n = 36) in
the cold phase and post reperfusion. The data show the relative abundances of the metabolites with 95% confidence intervals (statistics not applied
due to limited sample size).
doi:10.1371/journal.pone.0165884.g004
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DBD grafts. Some of the identified metabolic alterations correlate with our current under-
standing of the physiological changes surrounding DCD organ donation, including an impact
on glucose metabolism by donor warm ischaemia in DCD grafts. However, our observed
changes to the tryptophan/kynurenine axis in the DCD grafts are novel findings. Both of these
metabolites were observed at ca. 2-fold higher concentration in the DCD grafts (compared to
DBD grafts) in the cold phase, suggesting the possibility that these metabolites are responsible
for, or at least could be indicators of, the reported higher incidences of increased graft failures
in DCD grafts in the literature. In fact, we observed increased levels of tryptophan/kynurenine
in allografts with PNF in our study; however, due to few cases we were not able to verify statis-
tically verify this association. Given the role of metabolomics as a hypothesis generating tool,
and not to determine whether this metabolic pathway is indeed the cause of graft failure, we
conclude that the subsequent clinical investigations of DCD versus DBD transplantations
should employ a targeted analytical approach to robustly quantify the metabolites in the tryp-
tophan/kynurenine pathway in the pursuit of more reliable biomarkers of graft function.
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